News

The payment has been triggered by the successful transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403. The

A total of 214 patients have enrolled two months ahead of schedule in the clinical study of Urgent PC versus sham effectiveness in treatment of overactive bladder symptoms

David Brennan, chief executive officer, said: “AstraZeneca has delivered a robust performance in an increasingly challenging market environment. I am particularly pleased with our continued success in globalising

“SurModics achieved record revenue and earnings for the first quarter of fiscal 2009, driven primarily by the recognition of previously deferred revenue, which was triggered by Merck’s termination

Revenue for the fourth quarter was $78.6 million, as compared to total revenue of $107.6 million in the fourth quarter of 2007. For the fourth quarter of 2008,

These agreements stop all current litigation between the two parties in the fields of interventional cardiology and endovascular repair. All the disputes involved intellectual property. The stand-down agreements

Data obtained from animal studies have demonstrated that Ampakine compounds can specifically stimulate breathing by activating regions in the brain stem. In 2008, Cortex announced positive results of

“As previously announced, reduced demand in our Early Development segment from a combination of a lower level of new project initiations and increased project delays in our toxicology

Besides its lead drug, Ketotransdel (a topical nonsteroidal antiinflammatory drug currently in a Phase III trial for acute pain), the company is exploring potential co-development opportunities with corporate